Epalrestat, an aldose reductase inhibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients - Hamada,Y.; Nakamura,J.; Naruse,K. (Diabetes Care, 2000)